The prevalence of transmitted non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance around the world has been estimated up to 2010. Treatment recommendations have since evolved from NNRTIs to integrase strand inhibitors (INSTIs). This analysis estimates more recent trends in transmitted NNRTI resistance given emerging INSTI use. Studies reporting prevalence of transmitted NNRTI resistance in Europe, the United States, and Canada were meta-analyzed to generate yearly estimates in four regions. Overall prevalence of transmitted resistance continued to rise in the United States to >10% in 2015. Prevalence in European countries with larger surveillance networks was consistent at ∼4% from 2000 through 2012, increasing to 7% in 2016. Prevalence in European countries with fewer available data was generally <5%. Two publications with Canadian data were identified, reporting 0%–3% resistance. This analysis showed increasing prevalence of transmitted NNRTI resistance up to 2016, despite the availability of newer classes of treatments.

中文翻译：

---

简短交流：20 年来欧洲和北美国家对非核苷逆转录酶抑制剂的耐药性传播：更新的荟萃分析

据估计，截至 2010 年，世界范围内传播的非核苷逆转录酶抑制剂 (NNRTI) 耐药性的流行程度。治疗建议已从 NNRTIs 演变为整合酶链抑制剂 (INSTIs)。鉴于新出现的 INSTI 使用，该分析估计了传输的 NNRTI 抗性的最近趋势。对报告欧洲、美国和加拿大传播的 NNRTI 耐药性流行率的研究进行了元分析，以生成四个地区的年度估计值。2015 年，美国传播耐药性的总体流行率继续上升至 10% 以上。 2000 年至 2012 年，监测网络较大的欧洲国家的流行率一直保持在 4% 左右，2016 年上升至 7%。较少的可用数据通常<5%。确定了两份包含加拿大数据的出版物，报告了 0%–3% 的耐药性。该分析表明，截至 2016 年，传播 NNRTI 耐药性的流行率不断增加，尽管有更新的治疗方法可用。